Technical Data
Plexin A2 (Plexin-A2, PLXNA2, PLXN2, FLJ11751, FLJ30634, KIAA0463, OCT, Semaphorin Receptor OCT, UNQ209/PRO235)
Class 3 secreted semaphorin (Sema3A) is a chemorepellent that acts upon a wide variety of axons. As such, it induces a dramatic redistribution and depolymerization of actin filaments that results in growth cone collapse. Plexins are single membrane-spanning signaling proteins encompassing Plexin A1, A2, A3, and A4. Plexins form a complex with neuropilin-1 and -2 and the cell adhesion protein L1 to form a functional semaphorin receptor (1,2). The GTPase Rnd1 binds to the cytoplasmic domain of Plexin A1 to trigger cytoskeletal collapse. In contrast, the
GTPase RhoD blocks Rnd1-mediated Plexin A1 activation and repulsion of sympathetic axons by Sema3A (3). Sema6A is also a ligand for Plexin A2. Both Sema6A and Plexin A2 knock-out mice have a granule cell migration defect, where cells remain in the molecular layer. Furthermore,
Plexin A2 also controls nucleus–centrosome coupling which modulates cell migration (4).

Suitable for use in Western Blot and Immunoprecipitation. Other applications not tested.

Recommended Dilution:
Western Blot: 1:1000 Incubate membrane with diluted antibody in 5% BSA, 1X TBS, 0.1% Tween-20 at 4°C with gentle shaking, overnight.
Immunoprecipitation: 1:50
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
100ul-20°CBlue IceHumanRabbit
Not determined
Synthetic peptide corresponding to residues surrounding Gly185 of human Plexin A2.
Supplied as a liquid in 10mM sodium HEPES, pH 7.5, 150mM sodium chloride, 100ug/ml BSA, less than 0.02% sodium azide, 50% glycerol.
Recognizes endogenous levels of total Plexin A2. Species Crossreactivity: mouse, rat.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
(1) Pasterkamp, R.J. and Kolodkin, A.L. (2003) Curr Opin Neurobiol 13, 79-89. (2) Takahashi, T. and Strittmatter, S.M. (2001) Neuron 29, 429-39. (3) Zanata, S.M. et al. (2002) J Neurosci 22, 471-7.
(4) Renaud, J. et al. (2008) Nat Neurosci 11, 440-9.